Focus and breadth of cellular immune responses elicited by a heterologous insert prime-boost vaccine regimen in rhesus monkeys

Vaccine

Volumn 30, Issue 3, 2012, Pages 506-509

  Kaufman, David R ^a   Li, Fusheng ^b   Cruz, Ashley N ^a   Self, Steven G ^b   Barouch, Dan H ^a,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Statistical Center for HIV/AIDS Research and Prevention   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Cellular immune responses; Heterologous insert; HIV 1

Indexed keywords

ADENOVIRUS VECTOR; EPITOPE; GAG PROTEIN; RECOMBINANT ADENOVIRUS VECTOR; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; HETEROLOGOUS INSERT PRIME BOOST REGIMEN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SEROTYPE; VACCINATION; VIRUS REPLICATION;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; EPITOPES; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VARIATION; GENETIC VECTORS; HIV-1; IMMUNITY, CELLULAR; LYMPHOCYTES; MACACA MULATTA; VACCINATION; VACCINES, SYNTHETIC;

EID: 84355166378     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.079     Document Type: Article

References (19)

1. Carrington M., Nelson G.W., Martin M.P., Kissner T., Vlahov D., Goedert J.J., et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999, 283(5408):1748-1752.
2. Goulder P.J., Watkins D.I. HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 2004, 4(8):630-640.
3. Moore C.B., John M., James I.R., Christiansen F.T., Witt C.S., Mallal S.A. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002, 296(5572):1439-1443.
4. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283(5403):857-860.
5. Pereyra F., Jia X., McLaren P.J., Telenti A., de Bakker P.I., Walker B.D., et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010, 330(6010):1551-1557.
6. Barouch D.H., Kunstman J., Kuroda M.J., Schmitz J.E., Santra S., Peyerl F.W., et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002, 415(6869):335-339.
7. Goulder P.J., Phillips R.E., Colbert R.A., McAdam S., Ogg G., Nowak M.A., et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997, 3(2):212-217.
8. Yewdell J.W. Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 2006, 25(4):533-543.
9. Venturi V., Price D.A., Douek D.C., Davenport M.P. The molecular basis for public T-cell responses?. Nat Rev Immunol 2008, 8(3):231-238.
10. Kosmrlj A., Read E.L., Qi Y., Allen T.M., Altfeld M., Deeks S.G., et al. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 2010, 465(7296):350-354.
11. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372(9653):1894-1905.
12. Li F., McKenney D.M., Malhotra U., Crimi C., Nolin J., Corey L., et al. Towards prediction of degenerate CTL epitope recognition. Hum Vac 2008, 4(2):115-121.
13. Liu J., O'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2008, 457:87-91.
14. Barouch D.H., O'Brien K.L., Simmons N.L., King S.L., Abbink P., Maxfield L.F., et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010, 16(3):319-323.
15. Santra S., Korber B.T., Muldoon M., Barouch D.H., Nabel G.J., Gao F., et al. A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci USA 2008, 105(30):10489-10494.
16. Abbink P., Lemckert A.A., Ewald B.A., Lynch D.M., Denholtz M., Smits S., et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007, 81(9):4654-4663.
17. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004, 172(10):6290-6297.
18. Li F., Horton H., Gilbert P.B., McElrath J.M., Corey L., Self S.G. HIV-1 CTL-based vaccine immunogen selection: antigen diversity and cellular response features. Curr HIV Res 2007, 5(1):97-107.
19. Li F., Malhotra U., Gilbert P.B., Hawkins N.R., Duerr A.C., McElrath J.M., et al. Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine 2006, 24(47-48):6893-6904.